Plasma circulating miR-126 in patients with coronary artery heart disease and its effect on vascular endothelial cells

AIM: To investigate the role of plasma circulating miR-126 and miR-16 in the patients with coronary artery heart disease and to explore the influence of miR-126 on vascular endothelial cells. METHODS: Plasma total RNA was isolated from 52 patients with stable coronary artery disease and 52 healthy volunteers. The circulating miR-126 and miR-16 in those people were detected using specific primers. Endothelial cell line EA.hy926 was transfected with a miR -126 inhibitor, and total RNA of the cells was isolated 30 h after transfection to detect the expression level of vascular endothelial growth factor (VEGF). RESULTS: The expression of plasma circulating miR-126 was significantly decreased in the patients with coronary artery heart disease compared with healthy controls (P<0.05). No significant difference of circulating miR-16 between the patients with coronary artery heart disease and healthy controls was observed (P>0.05). The expression of VEGF in the endothelial cell line EA.hy926 transfected with miR-126 inhibitor was 2.08 times higher than that in negative control cells 30 h after transfection (P<0.05). CONCLUSION: Plasma circulating miR-126 is significantly decreased in the patients with coronary artery heart disease. Plasma circulating miR-16 in the patients with coronary artery heart disease and in the healthy controls is stable. miR-126 negatively regulates the expression of VEGF in vascular endothelial cells.